Colin Walsh
Director · Attovia Therapeutics, Inc.
Individual
- 2026
- Aug 28, 2026
- 2
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Colin Walsh files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GOLDMAN SACHS GROUP INC - $27.32M in ATTO purchases and sales in the last 12 months
- Redmile Group, LLC - $10.20M in ATTO purchases and sales in the last 12 months
- Frazier Life Sciences XI, L.P. - $10.00M in ATTO purchases and sales in the last 12 months
- venBio Global Strategic Fund IV, L.P. - $6.50M in ATTO purchases and sales in the last 12 months
- Sanofi - $5.10M in ATTO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Colin Walsh?
Colin Walsh is a corporate insider, tracked as Director of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Colin Walsh submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Colin Walsh been buying or selling stock?
Recorded transactions: 10 open-market purchases ($22.82M) and 46 open-market sales ($4.50M) across all tracked filings.
